BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Odio CM, Puig JR, Feris JM, Khan WN, Rodriguez WJ, McCracken GH Jr, Bradley JS. Prospective, randomized, investigator-blinded study of the efficacy and safety of meropenem vs. cefotaxime therapy in bacterial meningitis in children. Meropenem Meningitis Study Group. Pediatr Infect Dis J 1999;18:581-90. [PMID: 10440432 DOI: 10.1097/00006454-199907000-00004] [Cited by in Crossref: 78] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Toltzis P, Dul M, O’riordan MA, Melnick D, Lo M, Blumer J. Meropenem use and colonization by antibiotic-resistant Gram-negative bacilli in a pediatric intensive care unit*: . Pediatric Critical Care Medicine 2009;10:49-54. [DOI: 10.1097/pcc.0b013e318193691a] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
2 Grossi P, Gasperina DD. Treatment of Pseudomonas aeruginosa infection in critically ill patients. Expert Review of Anti-infective Therapy 2014;4:639-62. [DOI: 10.1586/14787210.4.4.639] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
3 Durrmeyer X, Cohen R. Utilisation des carbapénèmes en pédiatrie. Archives de Pédiatrie 2010;17:S163-70. [DOI: 10.1016/s0929-693x(10)70919-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Saf 2007;30:657-68. [PMID: 17696578 DOI: 10.2165/00002018-200730080-00002] [Cited by in Crossref: 59] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
5 Nudelman Y, Tunkel AR. Bacterial meningitis: epidemiology, pathogenesis and management update. Drugs 2009;69:2577-96. [PMID: 19943708 DOI: 10.2165/11530590-000000000-00000] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 2.1] [Reference Citation Analysis]
6 Miranda J, Tunkel AR. Strategies and new developments in the management of bacterial meningitis. Infect Dis Clin North Am 2009;23:925-43, viii-ix. [PMID: 19909891 DOI: 10.1016/j.idc.2009.06.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
7 Cottagnoud PH, Täuber MG. New therapies for pneumococcal meningitis. Expert Opin Investig Drugs 2004;13:393-401. [PMID: 15102588 DOI: 10.1517/13543784.13.4.393] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
8 Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 2014;69:2043-55. [PMID: 24744302 DOI: 10.1093/jac/dku111] [Cited by in Crossref: 57] [Cited by in F6Publishing: 45] [Article Influence: 7.1] [Reference Citation Analysis]
9 Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamic Evaluation of Meropenem and Cefotaxime for Pediatric Meningitis: A Report from the OPTAMA Program. Pediatric Drugs 2006;8:131-8. [DOI: 10.2165/00148581-200608020-00005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
10 Tan TQ. Pneumococcal conjugate vaccines — implications for community antibiotic prescribing. Current Opinion in Microbiology 2000;3:502-7. [DOI: 10.1016/s1369-5274(00)00130-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Randolph DA, Ward RM, Wade K, Valencia G, Burchfield D, Arrieta A, Mehta V, Walsh M, Kantak A, Rasmussen M, Sullivan JE, Finer N, Rich W, Brozanski BS, van den Anker J, Blumer J, Laughon M, Watt KM, Kearns GL, Capparelli EV, Martz K, Berezny K, Benjamin DK Jr, Smith PB; Meropenem Study Team. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections. Clin Infect Dis 2012;55:1495-502. [PMID: 22955430 DOI: 10.1093/cid/cis758] [Cited by in Crossref: 38] [Cited by in F6Publishing: 26] [Article Influence: 3.8] [Reference Citation Analysis]
12 Agrawal A, Cincu R, Timothy J. Current Concepts and Approach to Ventriculitis. Infectious Diseases in Clinical Practice 2008;16:100-4. [DOI: 10.1097/ipc.0b013e318142ce2c] [Cited by in Crossref: 22] [Article Influence: 1.6] [Reference Citation Analysis]
13 Sáez-Llorens X. Brain abscess in children. Semin Pediatr Infect Dis 2003;14:108-14. [PMID: 12881798 DOI: 10.1053/spid.2003.127227] [Cited by in Crossref: 47] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
14 Krysan DJ, Kemper AR. Claims of equivalence in randomized controlled trials of the treatment of bacterial meningitis in children. Pediatr Infect Dis J 2002;21:753-8. [PMID: 12192164 DOI: 10.1097/00006454-200208000-00011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
15 Paquet P, Jacob E, Damas P, Piérard GE. Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell’s syndrome) after putative β-lactam cross-reactivity: Case report and scrutiny of antibiotic imputability: . Critical Care Medicine 2002;30:2580-3. [DOI: 10.1097/00003246-200211000-00029] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
16 Jung Y, Kim HB. Multidrug-Resistant Gram-Positive Bacterial Infections. Korean J Med 2015;88:487. [DOI: 10.3904/kjm.2015.88.5.487] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
17 Ohata Y, Tomita Y, Sunakawa K, Drusano GL, Tanigawara Y. Cerebrospinal pharmacokinetic and pharmacodynamic analysis of efficacy of meropenem in paediatric patients with bacterial meningitis. Int J Antimicrob Agents 2019;54:292-300. [PMID: 31279154 DOI: 10.1016/j.ijantimicag.2019.06.021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Chowdhury MH, Tunkel AR. ANTIBACTERIAL AGENTS IN INFECTIONS OF THE CENTRAL NERVOUS SYSTEM. Infectious Disease Clinics of North America 2000;14:391-408. [DOI: 10.1016/s0891-5520(05)70254-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
19 Kaplan SL. Management of pneumococcal meningitis: . The Pediatric Infectious Disease Journal 2002;21:589-91. [DOI: 10.1097/00006454-200206000-00034] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
20 Tunkel AR, Van De Beek D, Scheld WM. Acute Meningitis. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Elsevier; 2010. pp. 1189-229. [DOI: 10.1016/b978-0-443-06839-3.00084-9] [Cited by in Crossref: 12] [Article Influence: 1.0] [Reference Citation Analysis]
21 Williams AJ, Nadel S. Bacterial meningitis: current controversies in approaches to treatment. CNS Drugs 2001;15:909-19. [PMID: 11735611 DOI: 10.2165/00023210-200115120-00001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
22 Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs 2008;68:803-38. [PMID: 18416587 DOI: 10.2165/00003495-200868060-00006] [Cited by in Crossref: 104] [Cited by in F6Publishing: 83] [Article Influence: 7.4] [Reference Citation Analysis]
23 Sinner SW, Tunkel AR. Antimicrobial agents in the treatment of bacterial meningitis. Infect Dis Clin North Am 2004;18:581-602, ix. [PMID: 15308277 DOI: 10.1016/j.idc.2004.04.005] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
24 McGill F, Heyderman RS, Michael BD, Defres S, Beeching NJ, Borrow R, Glennie L, Gaillemin O, Wyncoll D, Kaczmarski E, Nadel S, Thwaites G, Cohen J, Davies NW, Miller A, Rhodes A, Read RC, Solomon T. The UK joint specialist societies guideline on the diagnosis and management of acute meningitis and meningococcal sepsis in immunocompetent adults. J Infect 2016;72:405-38. [PMID: 26845731 DOI: 10.1016/j.jinf.2016.01.007] [Cited by in Crossref: 84] [Cited by in F6Publishing: 70] [Article Influence: 14.0] [Reference Citation Analysis]
25 Du X, Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. J Clin Pharmacol 2006;46:69-75. [PMID: 16397286 DOI: 10.1177/0091270005283283] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
26 Morita A, Kamei S, Minami M, Yoshida K, Kawabata S, Kuroda H, Suzuki Y, Araki N, Iwasaki Y, Kobayashi R, Hayashi N, Hirayama T, Ochiai J, Ueda M, Yamagishi Y, Niwa J, Shindo K, Fukushima Y, Takita T, Sato T, Sato S, Mikamo H, Iwata S. Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan. J Infect Chemother 2014;20:535-40. [PMID: 24882451 DOI: 10.1016/j.jiac.2014.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
27 Rivera-Chaparro ND, Cohen-Wolkowiez M, Greenberg RG. Dosing antibiotics in neonates: review of the pharmacokinetic data. Future Microbiol 2017;12:1001-16. [PMID: 28758800 DOI: 10.2217/fmb-2017-0058] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
28 Feigin RD, Cutrer WB. BACTERIAL MENINGITIS BEYOND THE NEONATAL PERIOD. Feigin and Cherry's Textbook of Pediatric Infectious Diseases. Elsevier; 2009. pp. 439-71. [DOI: 10.1016/b978-1-4160-4044-6.50042-x] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
29 Force E, Taberner F, Cabellos C, Ribes S, Domenech A, Tubau F, Viladrich PF, Gudiol F. Experimental study of meropenem in the therapy of cephalosporin-susceptible and -resistant pneumococcal meningitis. Eur J Clin Microbiol Infect Dis 2008;27:685-90. [PMID: 18386085 DOI: 10.1007/s10096-008-0492-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
30 Miller AD, Ball AM, Bookstaver PB, Dornblaser EK, Bennett CL. Epileptogenic potential of carbapenem agents: mechanism of action, seizure rates, and clinical considerations. Pharmacotherapy 2011;31:408-23. [PMID: 21449629 DOI: 10.1592/phco.31.4.408] [Cited by in Crossref: 68] [Cited by in F6Publishing: 44] [Article Influence: 6.2] [Reference Citation Analysis]
31 Tunkel AR, Scheld WM. Treatment of bacterial meningitis. Curr Infect Dis Rep 2002;4:7-16. [DOI: 10.1007/s11908-002-0062-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
32 Fakioglu E, Queenan AM, Bush K, Jenkins SG, Herold BC. Amp C beta-lactamase-producing Escherichia coli in neonatal meningitis: diagnostic and therapeutic challenge. J Perinatol 2006;26:515-7. [PMID: 16871223 DOI: 10.1038/sj.jp.7211550] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
33 Segal BH, Herbrecht R, Stevens DA, Ostrosky-Zeichner L, Sobel J, Viscoli C, Walsh TJ, Maertens J, Patterson TF, Perfect JR, Dupont B, Wingard JR, Calandra T, Kauffman CA, Graybill JR, Baden LR, Pappas PG, Bennett JE, Kontoyiannis DP, Cordonnier C, Viviani MA, Bille J, Almyroudis NG, Wheat LJ, Graninger W, Bow EJ, Holland SM, Kullberg BJ, Dismukes WE, De Pauw BE. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis 2008;47:674-83. [PMID: 18637757 DOI: 10.1086/590566] [Cited by in Crossref: 273] [Cited by in F6Publishing: 264] [Article Influence: 21.0] [Reference Citation Analysis]
34 Yogev R, Guzman-cottrill J. Bacterial Meningitis in Children: Critical Review of Current Concepts. Drugs 2005;65:1097-112. [DOI: 10.2165/00003495-200565080-00005] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
35 Knapp KM, English B. Carbapenems. Seminars in Pediatric Infectious Diseases 2001;12:175-85. [DOI: 10.1053/spid.2001.24093] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
36 Ruffmann C, Bogliun G, Beghi E. Epileptogenic drugs: a systematic review. Expert Review of Neurotherapeutics 2014;6:575-89. [DOI: 10.1586/14737175.6.4.575] [Cited by in Crossref: 46] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
37 Esposito S, Principi N. Pharmacotherapy for pneumococcal infections: an update. Expert Opin Pharmacother 2013;14:65-77. [PMID: 23256539 DOI: 10.1517/14656566.2013.756867] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
38 Maiques JM, Doménech A, Cabellos C, Fernández A, Ribes S, Tubau F, Gudiol F, Viladrich PF. Evaluation of antimicrobial regimens in a guinea-pig model of meningitis caused by Pseudomonas aeruginosa. Microbes Infect 2007;9:435-41. [PMID: 17350305 DOI: 10.1016/j.micinf.2006.12.013] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
39 Kaplan SL, Mason EO. Mechanisms of Pneumococcal Antibiotic Resistance and Treatment of Pneumococcal Infections in 2002. Pediatr Ann 2002;31:250-60. [DOI: 10.3928/0090-4481-20020401-09] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
40 Hameed N, Tunkel AR. Treatment of Drug-resistant Pneumococcal Meningitis. Curr Infect Dis Rep. 2010;12:274-281. [PMID: 21308542 DOI: 10.1007/s11908-010-0110-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
41 Ayalew K, Nambiar S, Yasinskaya Y, Jantausch BA. Carbapenems in pediatrics. Ther Drug Monit 2003;25:593-9. [PMID: 14508383 DOI: 10.1097/00007691-200310000-00009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
42 Sáez-Llorens X, McCoig C, Feris JM, Vargas SL, Klugman KP, Hussey GD, Frenck RW, Falleiros-Carvalho LH, Arguedas AG, Bradley J, Arrieta AC, Wald ER, Pancorbo S, McCracken GH Jr, Marques SR; Trovan menigitis Study Group. Quinolone treatment for pediatric bacterial meningitis: a comparative study of trovafloxacin and ceftriaxone with or without vancomycin. Pediatr Infect Dis J 2002;21:14-22. [PMID: 11791092 DOI: 10.1097/00006454-200201000-00004] [Cited by in Crossref: 48] [Cited by in F6Publishing: 36] [Article Influence: 2.4] [Reference Citation Analysis]
43 Hornik CP, Herring AH, Benjamin DK Jr, Capparelli EV, Kearns GL, van den Anker J, Cohen-Wolkowiez M, Clark RH, Smith PB; Best Pharmaceuticals for Children Act-Pediatric Trials Network. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants. Pediatr Infect Dis J 2013;32:748-53. [PMID: 23838776 DOI: 10.1097/INF.0b013e31828be70b] [Cited by in Crossref: 36] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
44 Shin SH, Kim KS. Treatment of bacterial meningitis: an update. Expert Opin Pharmacother 2012;13:2189-206. [PMID: 22984938 DOI: 10.1517/14656566.2012.724399] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
45 Ragnar Norrby S. Carbapenems in Serious Infections: A Risk-Benefit Assessment. Drug Safety 2000;22:191-4. [DOI: 10.2165/00002018-200022030-00003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
46 Planet PJ. Pseudomonas aeruginosa. Principles and Practice of Pediatric Infectious Diseases. Elsevier; 2018. pp. 866-870.e1. [DOI: 10.1016/b978-0-323-40181-4.00155-9] [Cited by in Crossref: 4] [Article Influence: 1.0] [Reference Citation Analysis]
47 Sullins AK, Abdel-Rahman SM. Pharmacokinetics of antibacterial agents in the CSF of children and adolescents. Paediatr Drugs. 2013;15:93-117. [PMID: 23529866 DOI: 10.1007/s40272-013-0017-5] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
48 Force E, Taberner F, Cabellos C, Ribes S, Doménech A, Tubau F, Viladrich PF, Gudiol F. Evaluation of meropenem alone and combined with rifampin in the guinea pig model of pneumococcal meningitis. Eur J Clin Microbiol Infect Dis 2009;28:807-11. [PMID: 19221815 DOI: 10.1007/s10096-009-0711-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
49 Brink M, Glimåker M, Sjölin J, Naucler P. Meropenem versus Cefotaxime and Ampicillin as Empirical Antibiotic Treatment in Adult Bacterial Meningitis: a Quality Registry Study, 2008 to 2016. Antimicrob Agents Chemother 2019;63:e00883-19. [PMID: 31501148 DOI: 10.1128/AAC.00883-19] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
50 Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39:1267-1284. [PMID: 15494903 DOI: 10.1086/425368] [Cited by in Crossref: 1286] [Cited by in F6Publishing: 921] [Article Influence: 71.4] [Reference Citation Analysis]
51 Ahmad F, Brubaker M, Rajendraprasad SS, Hoeynck B, Clyde BL, Velagapudi M. Challenges in the Management of Gram-Negative Bacterial Infections in Patients With Ventriculoperitoneal Shunt. Cureus 2021;13:e17035. [PMID: 34522514 DOI: 10.7759/cureus.17035] [Reference Citation Analysis]
52 Agrawal S, Nadel S. Acute bacterial meningitis in infants and children: epidemiology and management. Paediatr Drugs 2011;13:385-400. [PMID: 21999651 DOI: 10.2165/11593340-000000000-00000] [Cited by in Crossref: 41] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
53 Duke T, Curtis N, Fuller DG. The management of bacterial meningitis in children. Expert Opin Pharmacother 2003;4:1227-40. [PMID: 12877633 DOI: 10.1517/14656566.4.8.1227] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
54 Mohr JF 3rd. Update on the efficacy and tolerability of meropenem in the treatment of serious bacterial infections. Clin Infect Dis 2008;47 Suppl 1:S41-51. [PMID: 18713049 DOI: 10.1086/590065] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
55 Wen Z, Fan S, Du C, Yin T, Zhou B, Peng Z, Xie Y, Zhang W, Chen Y, Xiao J, Chen X. Drug-drug interaction between valproic acid and meropenem: a retrospective analysis of electronic medical records from neurosurgery inpatients. J Clin Pharm Ther 2017;42:221-7. [DOI: 10.1111/jcpt.12501] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
56 Drusano G, Lode H, Edwards J. Meropenem: clinical response in relation to in vitro susceptibility. Clinical Microbiology and Infection 2000;6:185-94. [DOI: 10.1046/j.1469-0691.2000.00062.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 14] [Article Influence: 0.4] [Reference Citation Analysis]